French biotech company Cellectis has appointed Professor Stéphane Depil to the role of senior vice president R&D and chief medical officer. 5 December 2017
There are a few striking similarities between the world’s biggest biotech firm focused on rare diseases, and an emerging clinical stage pharma company that was set up just a couple of years ago. 5 December 2017
The global life sciences and pharmaceuticals sector is undergoing a wave of strategic M&A activity, as incumbents make acquisitions to enhance the technological capabilities they need to keep pace with the evolution of the industry. 4 December 2017
Alligator Bioscience today announced the expansion of its management team with the appointment of Charlotte Russell as chief medical officer and Peter Ellmark as vice president discovery. 4 December 2017
Following the formation of a dedicated strategic business unit oncology earlier this year within its pharmaceuticals division, Germany’s Bayer announced today it will further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership. 1 December 2017
The Supervisory Board of Selvita has appointed Edyta Jaworska to the position of a management board member, responsible for the development of its integrated drug discovery services. 30 November 2017
The Russian government has surprisingly decided to make concessions to domestic and global drugmakers operating in the country through the extension of the time, required for the mandatory labeling of drugs, reports The Pharma Letter’s local correspondent. 30 November 2017
Russian biotech and biosimilars company Biocad is launching production in North Africa. As part of these plans, the company will start manufacturing of anti-cancer drugs at the facilities of the Moroccan pharmaceutical company SothemaLabs, reports The Pharma Letter’s local correspondent. 29 November 2017
Denmark-based allergy specialist ALK-Abelló today announced that Helle Skov, executive vice president of product supply and a member of ALK's board of management, leaves the company by mutual agreement. 29 November 2017
Charlie Johnson, chief executive of antibody drug conjugate (ADC) specialist ADC Bio, considers some of the challenges and solutions involved with developing ADC therapeutics in an Expert View piece. 29 November 2017
Mads Krogsgaard Thomsen, Novo Nordisk employee for over a quarter of a century, says he has "been through all the miserable failures as well as the successes of the company, from products that are now off patent to those that don't yet have one." 28 November 2017
Following reports in Israeli press last week that struggling generics giant Teva Pharmaceutical Industries is gearing up to slash its global workforce, the company announced today a radical shakeup of its executive team which included, as expected, the ousting of R&D chief Michael Hayden. 27 November 2017
As the crackdown on Canadian drug company Concordia International continues for overcharging the UK’s National Health Service by more than £100 million over the past decade, India's drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has identified over 601 suspected cases of overcharging where drug companies are not complying with the notified ceiling prices. 27 November 2017
Aside from issues concerning how to enforce second medical patents, the validity issues at the core of the Warner-Lambert case are on their way to the UK Supreme Court and have potentially significant implications for pharma patents, writes Andrew Hutchinson, a patent litigation partner at Simmons & Simmons LLP, in an Expert View piece. 23 November 2017
The National Immunobiological Company, Natsimbio, Russia’s leading vaccines’ producer, plans to invest 6 billion roubles (~$100 million) in the construction of a plant for the production of vaccines in the Russian city of Ufa, according to recent statements of the company's general director Maryam Khubieva. 20 November 2017
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024